Results-Unaudited Financial Statements For The Quarter And Half Year Ended 30th September 2025.

Qualified audit opinionAdverse audit opinionGoing-concern doubtRevenue growth above 20%Profit growth above 25%Results View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-4.7%Reaction day

₹0.64

prior close

₹0.64

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.1%-4.6% vs market

Pharmaceuticals peers, median of 157sector+0.0%-4.7% vs sector

On the reaction day the stock moved 4.6 pts less than Nifty Microcap 250 and 4.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-4.7

10m

-4.7

15m

-4.7

30m

-4.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-4.7-0.1-4.6+0.0-4.7

Next day

-9.4+0.5-9.9-0.1-9.2

-12.5-0.3-12.2-0.9-11.6

-15.6-0.5-15.1-1.3-14.3

-12.5-0.8-11.7-1.6-10.9

-9.4-2.3-7.1-2.3-7.1

-12.5-2.8-9.7-2.9-9.6

15d

-14.1-4.9-9.2-3.1-11.0

-23.4-4.7-18.7-4.3-19.2

-39.1-7.7-31.3-5.6-33.4

-45.3-7.8-37.5-10.3-35.1

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

The company reported unaudited Q2 FY26 revenue of ₹6,562.38 lacs (vs ₹2,455 lacs in Q2 FY25) and H1 FY26 revenue of ₹36,553.83 lacs. Profit after tax for Q2 was ₹850.47 lacs (vs ₹183.83 lacs) and H1 PAT was ₹3,180.41 lacs. However, the statutory auditor issued a Disclaimer of Opinion stating they could not verify sales, purchases, inventory valuation, trade receivables, unsecured loans (no agreements), and that no Fixed Assets register was provided. The entire reported business has shifted to a new 'Agriculture' segment, with the previously dominant Drugs & Pharmaceutical segment showing zero revenue. Management blamed the audit issues on lack of records from the previous management.

Likely market impact

Despite the strong reported numbers, the auditor's disclaimer means the financial statements are unreliable and the figures cannot be relied upon. Shareholders should treat the headline growth with extreme caution as the books may be materially misstated, and this is a significant red flag for the stock.